Group 1 - The stock of Israeli clinical biopharmaceutical company UroGen Pharma (ADR) has resumed trading, experiencing a 63% increase [1] - UroGen Pharma focuses on developing novel therapies aimed at changing the standard of care for urological pathology [1] Group 2 - The stock price reached a high of $12.50 and a low of $6.92, with a previous close of $7.30 [3] - The trading volume was 1.97 million shares, with a turnover rate of 4.27% [3] - The stock's market capitalization is approximately $535 million, with a 52-week high of $20.70 and a low of $3.42 [3]